183 related articles for article (PubMed ID: 35503656)
1. CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity.
Modak M; Mattes AK; Reiss D; Skronska-Wasek W; Langlois R; Sabarth N; Konopitzky R; Ramirez F; Lehr K; Mayr T; Kind D; Viollet C; Swee LK; Petschenka J; El Kasmi KC; Noessner E; Kitt K; Pflanz S
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35503656
[TBL] [Abstract][Full Text] [Related]
2. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
[TBL] [Abstract][Full Text] [Related]
3. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
4. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
[TBL] [Abstract][Full Text] [Related]
5. Critical role of CD206+ macrophages in promoting a cDC1-NK-CD8 T cell anti-tumor immune axis.
Ray A; Hu KH; Kersten K; Courau T; Kuhn NF; Zaleta-Linares I; Samad B; Combes AJ; Krummel MF
bioRxiv; 2024 Jun; ():. PubMed ID: 37961697
[TBL] [Abstract][Full Text] [Related]
6. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
7. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
9. Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review.
Lecoultre M; Dutoit V; Walker PR
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335026
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
Cioca DP; Deak E; Cioca F; Paunescu V
J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
12. Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8
Booty MG; Hlavaty KA; Stockmann A; Ozay EI; Smith C; Tian L; How E; Subramanya D; Venkitaraman A; Yee C; Pryor O; Volk K; Blagovic K; Vicente-Suarez I; Yarar D; Myint M; Merino A; Chow J; Abdeljawad T; An H; Liu S; Mao S; Heimann M; Talarico L; Jacques MK; Chong E; Pomerance L; Gonzalez JT; von Andrian UH; Jensen KF; Langer R; Knoetgen H; Trumpfheller C; Umaña P; Bernstein H; Sharei A; Loughhead SM
J Immunol; 2022 Feb; 208(4):929-940. PubMed ID: 35091434
[TBL] [Abstract][Full Text] [Related]
13. Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells.
Manches O; Lui G; Molens JP; Sotto JJ; Chaperot L; Plumas J
Cytotherapy; 2008; 10(6):642-9. PubMed ID: 18836919
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
15. Induced pluripotent stem cell-derived myeloid cells expressing OX40 ligand amplify antigen-specific T cells in advanced melanoma.
Kimura T; Fukushima S; Okada E; Kuriyama H; Kanemaru H; Kadohisa-Tsuruta M; Kubo Y; Nakahara S; Tokuzumi A; Kajihara I; Makino K; Miyashita A; Aoi J; Makino T; Tsukamoto H; Nishimura Y; Inozume T; Zhang R; Uemura Y; Senju S; Ihn H
Pigment Cell Melanoma Res; 2020 Sep; 33(5):744-755. PubMed ID: 32353897
[TBL] [Abstract][Full Text] [Related]
16. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity.
Saccheri F; Pozzi C; Avogadri F; Barozzi S; Faretta M; Fusi P; Rescigno M
Sci Transl Med; 2010 Aug; 2(44):44ra57. PubMed ID: 20702856
[TBL] [Abstract][Full Text] [Related]
17. Clec9A
Gilfillan CB; Kuhn S; Baey C; Hyde EJ; Yang J; Ruedl C; Ronchese F
J Immunol; 2018 Apr; 200(8):2978-2986. PubMed ID: 29507107
[TBL] [Abstract][Full Text] [Related]
18. A Brucella spp. Protease Inhibitor Limits Antigen Lysosomal Proteolysis, Increases Cross-Presentation, and Enhances CD8+ T Cell Responses.
Coria LM; Ibañez AE; Tkach M; Sabbione F; Bruno L; Carabajal MV; Berguer PM; Barrionuevo P; Schillaci R; Trevani AS; Giambartolomei GH; Pasquevich KA; Cassataro J
J Immunol; 2016 May; 196(10):4014-29. PubMed ID: 27084100
[TBL] [Abstract][Full Text] [Related]
19. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
